nach oben

Digestive Diseases and Sciences

Erschienen in:

01.01.2009 | Original Article

The Effect of iNOS Inhibitors and Hyperbaric Oxygen Treatment in a Rat Model of Experimental Colitis

verfasst von: Cemal Nuri Ercin, Zeki Yesilova, Ahmet Korkmaz, Ayhan Ozcan, Cagatay Oktenli, Ahmet Uygun

Erschienen in: Digestive Diseases and Sciences | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Aim Our aim was to investigate the effectiveness of aminoguanidine (AMG), an inducible nitric oxide synthase inhibitor, and hyperbaric oxygen (HBO) treatment in an experimental colitis model. Methods We induced colitis in rats. In the control group, we applied 2 ml serum physiologic intraperitoneally for 7 days. In the HBO group, 100% oxygen at 2.4 atm pressure was applied for 7 days. In the AMG group, 100 mg/kg AMG was applied intraperitoneally for 7 days. In the HBO + AMG group, HBO and AMG were applied, respectively. At the end of 7 days, rats were sacrificed and the distal 10 cm part of colon was examined macro- and microscopically. Results Severity of colitis and NO activities were reduced by AMG, HBO, and HBO + AMG application. There was histologically significant improvement, especially in the HBO + AMG group Conclusions Both HBO and AMG were significantly effective in preventing weight loss, reducing NO activities, and severity of colitis, when comparing HBO and AMG separately.

Pettersson S. Introduction: Inflammatory bowel disease: A complex systemic disease engaging multiple players outside the immune system. J Intern Med. 2008;263:574–576. doi:10.1111/j.1365-2796.2008.01973.x.PubMedCrossRef

Pavlick KP, Laroux FS, Fuseler J, et al. Role of reactive metabolities of oxygen and nitrogen in inflammatory bowel disease. Free Radic Biol Med. 2002;33:311–322. doi:10.1016/S0891-5849(02)00853-5.PubMedCrossRef

Grisham MB. Oxidants and free radicals in inflammatory bowel disease. Lancet. 1994;344:859–861. doi:10.1016/S0140-6736(94)92831-2.PubMedCrossRef

Harris ML, Schiller HJ, Reilly PM, Donowitz M, Grisham MB, Bulkley GB. Free radicals and other reactive oxygen metabolities in inflammatory bowel disease: Cause, consequence or epiphenomenon? Pharmacol Ther. 1992;53:375–408. doi:10.1016/0163-7258(92)90057-7.PubMedCrossRef

Cross RK, Wilson KT. Nitric oxide in inflammatory bowel disease. Inflamm Bowel Dis. 2003;9:179–189. doi:10.1097/00054725-200305000-00006.PubMedCrossRef

Singer II, Kawka DW, Scott S, et al. Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology. 1996;111:871–875. doi:10.1016/S0016-5085(96)70055-0.PubMedCrossRef

Grisham MB, Specian RD, Zimmerman TE. Effects of nitric oxide synthase inhibition on the pathophysiology observed in a model of chronic granulomatous colitis. J Pharmacol Exp Ther. 1994;271:1114–1121.PubMed

Rachmilewitz D, Karmeli F, Okon E, Bursztyn M. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Gut. 1995;37:247–255. doi:10.1136/gut.37.2.247.PubMedCrossRef

Rachmilewitz D, Karmeli F, Okon E. Sulfhydryl blocker-induced rat colonic inflammation is ameliorated by inhibition of nitric oxide synthase. Gastroenterology. 1995;109:98–106. doi:10.1016/0016-5085(95)90273-2.PubMedCrossRef

10.

Grim PS, Gottlieb LJ, Boddie A, Batson E. Hyperbaric oxygen therapy. JAMA. 1990;263:2216–2220. doi:10.1001/jama.263.16.2216.PubMedCrossRef

11.

Lavy A, Weisz G, Adir Y, Ramon Y, Melamed Y, Eidelman S. Hyperbaric oxygen for perianal Crohn’s disease. J Clin Gastroenterol. 1994;19:202–205. doi:10.1097/00004836-199410000-00006.PubMedCrossRef

12.

Rachmilewitz D, Karmeli F, Okon E, Rubenstein I, Better OS. Hyperbaric oxygen: A novel modality to ameliorate experimental colitis. Gut. 1998;43:512–518.PubMedCrossRef

13.

Colombel JF, Mathieu D, Bouault JM, et al. Hyperbaric oxygenation in severe perineal Crohn’s disease. Dis Colon Rectum. 1995;38:609–614. doi:10.1007/BF02054120.PubMedCrossRef

14.

Jurjus AR, Khoury NN, Reimund JM. Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods. 2004;50:81–92. doi:10.1016/j.vascn.2003.12.002.PubMedCrossRef

15.

Yuan H, Ji WS, Wu KX, Jiao JX, Sun LH, Feng YT. Anti-inflammatory effect of Diammonium Glycyrrhizinate in a rat model of ulcerative colitis. World J Gastroenterol. 2006;12:4578–4581.PubMed

16.

Tsikas D. Analysis of nitrite and nitrate in biological fluids by assays based on the Griess reaction: Appraisal of the Griess reaction in the l-arginine/nitric oxide area of research. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;851:51–70. doi:10.1016/j.jchromb.2006.07.054.PubMedCrossRef

17.

Butler AR, Flitney FW, Williams DL. NO, nitrosonium ions, nitroxide ions, nitrosothiols and iron-nitrosyls in biology: a chemist’s perspective. Trends Pharmacol Sci. 1995;16:18–22. doi:10.1016/S0165-6147(00)88968-3.PubMedCrossRef

18.

Takahashı T. Pathophysiological significance of neuronal nitric oxide synthase in the gastrointestinal tract. J Gastroenterol. 2003;38:421–430. doi:10.1007/s00535-003-1094-y.PubMedCrossRef

19.

Cuzzocrea S, McDonald MC, Mazzon E, et al. Tempol, a membrane-permeable radical scavenger, reduces dinitrobenzene sulfonic acid-induced colitis. Eur J Pharmacol. 2000;406:127–137. doi:10.1016/S0014-2999(00)00623-3.PubMedCrossRef

20.

Zingarelli B, Cuzzocrea S, Szabo C, Salzman AL. Mercaptoethylguanidine, a combined inhibitor of nitric oxide synthase and peroxynitrite scavenger, reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. J Pharmacol Exp Ther. 1998;287:1048–1055.PubMed

21.

Roediger WE, Lawson MJ, Nance SH, Radcliffe BC. Detectable colonic nitrite levels in inflammatory bowel disease-mucosal or bacterial mulfunction? Digestion. 1986;35:199–204.PubMedCrossRef

22.

Middleton SJ, Shorthouse M, Hunter JO. Increased nitric oxide synthesis in ulcerative colitis. Lancet. 1993;341:465–466. doi:10.1016/0140-6736(93)90211-X.PubMedCrossRef

23.

Rachmilewitz D, Stamler JS, Bachwich D, Karmeli F, Ackerman Z, Podolsky DK. Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn’s disease. Gut. 1995;36:718–723. doi:10.1136/gut.36.5.718.PubMedCrossRef

24.

Rachmilewitz D, Eliakim R, Ackerman Z, Karmeli F. Direct determination of colonic nitric oxide level—a sensitive marker of disease activity in ulcerative colitis. Am J Gastroenterol. 1998;93:409–412.PubMed

25.

Hogaboam CM, Jacobson K, Collins SM, Blennerhassett MG. The selective beneficial effects of nitric oxide inhibition in experimental colitis. Am J Physiol. 1995;268:G673–G684.PubMed

26.

Perner A, Andresen L, Normark M, et al. Expression of nitric oxide synthases and effects of L-arginine and L-NMMA on nitric oxide production and fluid transport in collagenous colitis. Gut. 2001;49:387–394. doi:10.1136/gut.49.3.387.PubMedCrossRef

27.

Kankuri E, Hamalainen M, Hukkanen M, et al. Suppression of pro-inflammatory cytokine release by selective inhibition of inducible nitric oxide synthase in mucosal explants from patients with ulcerative colitis. Scand J Gastroenterol. 2003;38:186–192. doi:10.1080/00365520310000681.PubMedCrossRef

28.

Pilichos CJ, Kouerinis IA, Zografos GC, et al. The effect of nitric oxide synthases inhibitors on inflammatory bowel disease in a rat model. In Vivo. 2004;18:513–516.PubMed

29.

Dudhgaonkar SP, Tandan SK, Kumar D, Raviprakash V, Kataria M. Influence of simultaneous inhibition of cyclooxygenase-2 and inducible nitric oxide synthase in experimental colitis in rats. Inflammopharmacol. 2007;15:188–195. doi:10.1007/s10787-007-1603-3.CrossRef

30.

Nakamura H, Tsukada H, Oya M, et al. Aminoguanidine has both an anti-inflammatory effect on experimental colitis and a proliferative effect on colonic mucosal cells. Scand J Gastroenterol. 1999;34:1117–1122. doi:10.1080/003655299750024922.PubMedCrossRef

31.

Cuthbertson CM, Christophi C. Potential effects of hyperbaric oxygen therapy in acute pancreatitis. ANZ J Surg. 2006;76:625–630. doi:10.1111/j.1445-2197.2006.03793.x.PubMedCrossRef

32.

Christophi C, Millar I, Nikfarjam M, Muralidharan V, Malcontenti-Wilson C. Hyperbaric oxygen therapy for severe acute pancreatitis. J Gastroenterol Hepatol. 2007;22:2042–2046. doi:10.1111/j.1440-1746.2006.03380.x.PubMedCrossRef

33.

Alex J, Laden G, Cale AR, et al. Pretreatment with hyperbaric oxygen and its effect on neuropsychometric dysfunction and systemic inflammatory response after cardiopulmonary bypass: A prospective randomized double-blind trial. J Thorac Cardiovasc Surg. 2005;130:1623–1630. doi:10.1016/j.jtcvs.2005.08.018.PubMedCrossRef

34.

Marshall GT, Thirlby RC, Bredfeldt JE, Hampson NB. Treatment of gastrointestinal radiation injury with hyperbaric oxygen. Undersea Hyperb Med. 2007;34:35–42.PubMed

35.

Filntisis GA, Moon RE, Kraft KL, Farmer JC, Scher RL, Piantadosi CA. Laryngeal radionecrosis and hyperbaric oxygen therapy: Report of 18 cases and review of the literature. Ann Otol Rhinol Laryngol. 2000;109:554–562.PubMed

36.

Gürbüz AK, Elbüken E, Yazgan Y, Yildiz S. A different therapeutic approach in patients with severe ulcerative colitis: Hyperbaric oxygen treatment. South Med J. 2003;96:632–633. doi:10.1097/01.SMJ.0000074507.31006.79.PubMedCrossRef

37.

Gorgulu S, Yagci G, Kaymakcioglu N, et al. Hyperbaric oxygen enhances the efficiency of 5-aminosalicylic acid in acetic acid-induced colitis in rats. Dig Dis Sci. 2006;51:480–487. doi:10.1007/s10620-006-3159-2.PubMedCrossRef

38.

Demirtürk L, Ozel M, Yazgan Y, Buchman AL. Therapeutic efficacy of hyperbaric oxygenation in ulcerative colitis refractory to medical treatment. J Clin Gastroenterol. 2002;35:286–287. doi:10.1097/00004836-200209000-00021.PubMedCrossRef

39.

Buchman AL, Fife C, Torres C, Smith L, Aristizibal J. Hyperbaric oxygen therapy for severe ulcerative colitis. J Clin Gastroenterol. 2001;33:337–339. doi:10.1097/00004836-200110000-00018.PubMedCrossRef

40.

Gulec B, Yasar M, Yildiz S, et al. Effect of hyperbaric oxygen on experimental acute distal colitis. Physiol Res. 2004;53:493–499.PubMed

41.

Atug O, Hamzaoglu H, Tahan V, et al. Hyperbaric oxygen therapy is as effective as dexamethasone in the treatment of TNBS-E-induced experimental colitis. Dig Dis Sci. 2008;53:481–485. doi:10.1007/s10620-007-9956-4.PubMedCrossRef

42.

Akin ML, Gulluoglu BM, Uluutku H, et al. Hyperbaric oxygen improves healing in experimental rat colitis. Undersea Hyperb Med. 2002;29:279–285.PubMed

43.

Lin HC, Wan FJ, Wu CC, Tung CS, Wu TH. Hyperbaric oxygen protects against lipopolysaccharide-stimulated oxidative stress and mortality in rats. Eur J Pharmacol. 2005;508:249–254. doi:10.1016/j.ejphar.2004.12.021.PubMedCrossRef

Titel: The Effect of iNOS Inhibitors and Hyperbaric Oxygen Treatment in a Rat Model of Experimental Colitis
verfasst von: Cemal Nuri Ercin
Zeki Yesilova
Ahmet Korkmaz
Ayhan Ozcan
Cagatay Oktenli
Ahmet Uygun
Publikationsdatum: 01.01.2009
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 1/2009
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-008-0498-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2009

Twenty-Five Years of Research on Saccharomyces boulardii Trophic Effects: Updates and Perspectives

Helicobacter pylori vacA Arrangement and Related Diseases: A Retrospective Study Over a Period of 15 Years

Clinical Presentation and Patterns of Slow Transit Constipation Do Not Predict Coexistent Upper Gut Dysmotility

A Case of Churg-Strauss Syndrome Revealed by Eosinophilic Gastroenteritis

Gastroenterology Research Group and Digestive Diseases and Sciences